Plain-English translation of NCT06439914 on ClinicalTrials.gov β Β· Source last updated Β· Translation generated Β· How we translate trials
Phase 1 β Testing in a small group (usually 20β80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is an early-stage study testing a new imaging agent called that could help doctors see how your body is responding to immunotherapy for lung cancer. The medication is injected into your bloodstream, and then special PET scans take pictures to show how your immune system is fighting the cancer. Researchers hope this new type of scan will help predict which patients will benefit most from immunotherapy.
Currently, doctors have to wait weeks or months to know if immunotherapy is working by looking at tumor size on standard scans. This study hopes to create a faster, earlier way to see whether the treatment is helping, so doctors can make better decisions about your care sooner.
You likely qualify ifβ¦
You likely don't qualify ifβ¦
You will have screening tests including blood work, a medical history review, and a physical exam. Within 14 days of starting immunotherapy, you'll receive an injection of the imaging medication and then complete three PET scans over a few days (at 1-2 hours, the next day, and 3-5 days after injection). This scan sequence may be repeated once more about 4-6 weeks later, for a total of up to six scans. The whole study lasts about 1.5 months, and each scan appointment takes about 30-60 minutes.
AI-generated summary from trial data Β· Jun 18, 2026 Β· Not medical advice
United States